N/A N=31 Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Change in Development of Hair Loss — 30; 0; 0; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 Pre-exposure Prophylaxis Implementation in Central-Eastern European Countries
Human Immunodeficiency Virus
Primary: PrEP Adherence Via Biological Measures (Binary) — 47; 34; 11; 19 Participants
Phase 3 N=304 Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)
Lesion in Body Region
Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.79; 2.26; 3.48; 3.01 mean of a score (on a scale) per patient — p=< 0.0001
Phase 4 N=152 Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)
Respiratory Syncytial Virus (RSV)
Primary: Geometric Mean Fold Rise Against RSV Fa Protein — 12.5; 9.9 fold change — p=0.14
Phase 2 N=20 High Dose Risankizumab for Psoriasis
Psoriasis
Primary: CD8+ Trm1 Cells in Lesional Skin at Baseline and Week 52 — 9.60; 26.71; 1.60; 16.63 number of cells
N/A N=101 Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:
Rheumatoid Arthritis · Cardiovascular Diseases · Hyperlipidemias
Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…
Phase 3 N=102 A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
Relapsing Forms of Multiple Sclerosis
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 50; 45; 3; 5 Participants
Phase 2 N=86 Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Adenocarcinoma of the Prostate
Primary: Percent of Participants With Freedom of PSA (Prostate Specific Antigen) Progression — 84; 66 Percent of patients with no progession
Phase 2 N=189 An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
Resistant Hypertension
Primary: Dose-response (DR) Relationship of XXB750 With Respect to Change From Baseline in Systolic Blood Pressure (SBP) 24 Hours — -5.77; -6.41; -6.63; -6.66 mmHg — p=0.5651
N/A N=184 Mobile Web-based Behavioral Intervention for Improving Caregiver Well-being
Depressive Symptoms · Stress, Psychological
Primary: Center for Epidemiologic Studies Depression Scale--Revised (CESD-R) — 16.9; 14.9 Score on a scale
N/A N=669 A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint (PSE): Event Rate of Safety Events Post Procedure — 2.3; 2.4 Percentage of participants
Phase 2 N=637 Promoting Informed Choice for Breast Cancer Screening
Breast Cancer
Primary: Reactance — 2.28; 2.45; 2.55 score on a scale
N/A N=47 Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction
Improvement of Dry Eye Disease
Primary: Standardized Patient Evaluation of Eye Dryness (SPEED) — 9.6 score on a scale — p=<0.001
Phase 2 N=71 Evaluation of Single Session Stereotactic Body Radiotherapy
Spinal Neoplasms
Primary: Complete Pain Relief Using Stereotactic Body Radiotherapy (SBRT) to Treat Spine and Para- Spinal Tumors in a Single Session — 18 Participants
Phase 2 N=54 A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Number of Participants With Any Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03) — 7; 9; 6; 4 Participants